Literature DB >> 27773498

Comparative pharmacodynamics of four different carbapenems in combination with polymyxin B against carbapenem-resistant Acinetobacter baumannii.

Justin R Lenhard1, Jonathan S Gall2, Jurgen B Bulitta3, Visanu Thamlikitkul4, Cornelia B Landersdorfer5, Alan Forrest6, Roger L Nation5, Jian Li5, Brian T Tsuji7.   

Abstract

The objective of this study was to determine the comparative pharmacodynamics of four different carbapenems in combination with polymyxin B (PMB) against carbapenem-resistant Acinetobacter baumannii isolates using time-kill experiments at two different inocula. Two A. baumannii strains (03-149-1 and N16870) with carbapenem minimum inhibitory concentrations (MICs) ranging from 8 to 64 mg/L were investigated in 48-h time-kill experiments using starting inocula of 106 CFU/mL and 108 CFU/mL. Concentration arrays of ertapenem, doripenem, meropenem and imipenem at 0.25×, 0.5×, 1×, 1.5× and 2× published maximum serum concentration (Cmax) values (Cmax concentrations of 12, 21, 48 and 60 mg/L, respectively) were investigated in the presence of 1.5 mg/L PMB. Use of carbapenems without PMB resulted in drastic re-growth. All carbapenem combinations were able to achieve a ≥3 log10 CFU/mL reduction by 4 h against both strains at 106 CFU/mL, whereas maximum reductions against strain 03-149-1 at 108 CFU/mL were 1.0, 3.2, 2.2 and 3.3 log10 CFU/mL for ertapenem, doripenem, meropenem and imipenem, respectively. None of the combinations were capable of reducing 108 CFU/mL of N16870 by ≥2 log10 CFU/mL. Ertapenem combinations consistently displayed the least activity, whereas doripenem, meropenem and imipenem combinations had similar activities that were poorly predicted by carbapenem MICs. As doripenem, meropenem, or imipenem displayed similar pharmacodyanmics in combination, the decision of which carbapenem to use in combination with PMB may be based on toxicodynamic profiles if drastic discordance in MICs is not present.
Copyright © 2016. Published by Elsevier B.V.

Entities:  

Keywords:  Acinetobacter baumannii; Carbapenem resistance; Polymyxins

Mesh:

Substances:

Year:  2016        PMID: 27773498      PMCID: PMC5237376          DOI: 10.1016/j.ijantimicag.2016.07.024

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  20 in total

1.  Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii.

Authors:  Jian Li; Craig R Rayner; Roger L Nation; Roxanne J Owen; Denis Spelman; Kar Eng Tan; Lisa Liolios
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

2.  Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens.

Authors:  Ana M Sandri; Cornelia B Landersdorfer; Jovan Jacob; Márcio M Boniatti; Micheline G Dalarosa; Diego R Falci; Tainá F Behle; Rosaura C Bordinhão; Jiping Wang; Alan Forrest; Roger L Nation; Jian Li; Alexandre P Zavascki
Journal:  Clin Infect Dis       Date:  2013-05-22       Impact factor: 9.079

3.  In vitro interactions of antimicrobial combinations with fosfomycin against KPC-2-producing Klebsiella pneumoniae and protection of resistance development.

Authors:  Maria Souli; Irene Galani; Stefanos Boukovalas; Michael George Gourgoulis; Zoi Chryssouli; Kyriaki Kanellakopoulou; Theofano Panagea; Helen Giamarellou
Journal:  Antimicrob Agents Chemother       Date:  2011-02-14       Impact factor: 5.191

4.  Evaluation of double- and triple-antibiotic combinations for VIM- and NDM-producing Klebsiella pneumoniae by in vitro time-kill experiments.

Authors:  T Tängdén; R A Hickman; P Forsberg; P Lagerbäck; C G Giske; O Cars
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

5.  Evolution of Staphylococcus aureus under vancomycin selective pressure: the role of the small-colony variant phenotype.

Authors:  Justin R Lenhard; Christof von Eiff; Irene S Hong; Patricia N Holden; Michael D Bear; Amy Suen; Zackery P Bulman; Brian T Tsuji
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

6.  Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Authors:  Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

Review 7.  Pharmacology of polymyxins: new insights into an 'old' class of antibiotics.

Authors:  Tony Velkov; Kade D Roberts; Roger L Nation; Philip E Thompson; Jian Li
Journal:  Future Microbiol       Date:  2013-06       Impact factor: 3.165

Review 8.  Acinetobacter baumannii: emergence of a successful pathogen.

Authors:  Anton Y Peleg; Harald Seifert; David L Paterson
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

Review 9.  Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems.

Authors:  Oren Zusman; Tomer Avni; Leonard Leibovici; Amos Adler; Lena Friberg; Theodouli Stergiopoulou; Yehuda Carmeli; Mical Paul
Journal:  Antimicrob Agents Chemother       Date:  2013-08-05       Impact factor: 5.191

Review 10.  Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence.

Authors:  Matthew E Falagas; Panagiota Lourida; Panagiotis Poulikakos; Petros I Rafailidis; Giannoula S Tansarli
Journal:  Antimicrob Agents Chemother       Date:  2013-09-30       Impact factor: 5.191

View more
  7 in total

1.  Inoculum effect of β-lactam antibiotics.

Authors:  Justin R Lenhard; Zackery P Bulman
Journal:  J Antimicrob Chemother       Date:  2019-10-01       Impact factor: 5.790

Review 2.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 3.  Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options.

Authors:  Chang-Ro Lee; Jung Hun Lee; Moonhee Park; Kwang Seung Park; Il Kwon Bae; Young Bae Kim; Chang-Jun Cha; Byeong Chul Jeong; Sang Hee Lee
Journal:  Front Cell Infect Microbiol       Date:  2017-03-13       Impact factor: 5.293

4.  Synergy effect of meropenem-based combinations against Acinetobacter baumannii: a systematic review and meta-analysis.

Authors:  Zhihui Jiang; Xianxia He; Jian Li
Journal:  Infect Drug Resist       Date:  2018-08-07       Impact factor: 4.003

Review 5.  Generating Robust and Informative Nonclinical In Vitro and In Vivo Bacterial Infection Model Efficacy Data To Support Translation to Humans.

Authors:  Jürgen B Bulitta; William W Hope; Ann E Eakin; Tina Guina; Vincent H Tam; Arnold Louie; George L Drusano; Jennifer L Hoover
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

6.  A polytherapy based approach to combat antimicrobial resistance using cubosomes.

Authors:  Xiangfeng Lai; Mei-Ling Han; Yue Ding; Seong Hoong Chow; Anton P Le Brun; Chun-Ming Wu; Phillip J Bergen; Jhih-Hang Jiang; Hsien-Yi Hsu; Benjamin W Muir; Jacinta White; Jiangning Song; Jian Li; Hsin-Hui Shen
Journal:  Nat Commun       Date:  2022-01-17       Impact factor: 14.919

Review 7.  Losing the Battle but Winning the War: Can Defeated Antibacterials Form Alliances to Combat Drug-Resistant Pathogens?

Authors:  Song Oh; Raymond Chau; Anh T Nguyen; Justin R Lenhard
Journal:  Antibiotics (Basel)       Date:  2021-05-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.